RTW Biotech OpportunitiesLSE:RTW -1.62%42 PS Ratio is 4.45 as of Jul. 06, 2026, which is 9% above its 10-year median of 4.10. GuruFocus rates LSE:RTW with a GF Score™ of 42/100. The stock has 2 warning signs investors should review. Among 1,408 Asset Management companies, RTW Biotech Opportunities ranks better than 68.39% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, RTW Biotech Opportunities's share price is $2.43.
RTW Biotech Opportunities's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.55. Hence, RTW Biotech Opportunities's PS Ratio for today is 4.45.
The historical rank and industry rank for RTW Biotech Opportunities's PS Ratio or its related term are showing as below:
LSE:RTW'
s PS Ratio Range Over the Past 10 Years
Min: 2.33 Med: 4.1 Max: 17.68
Current: 4.45
During the past 8 years, RTW Biotech Opportunities's highest PS Ratio was 17.68. The lowest was 2.33. And the median was 4.10.
LSE:RTW's PS Ratio is ranked better than 68.39% of 1408
companies
in the Asset Management industry
Industry Median: 7.275
vs LSE:RTW: 4.45
During the past 8 years, RTW Biotech Opportunities's highest 3-Year average Revenue per Share Growth Rate was -18.10% per year. The lowest was -18.10% per year. And the median was -18.10% per year.
Back to Basics: PS Ratio
RTW Biotech Opportunities (LSE:RTW) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
RTW Biotech Opportunities PS Ratio Related Terms
RTW Biotech Opportunities PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities PS Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's PS Ratio distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
RTW Biotech Opportunities's Share Price of today is $2.43.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RTW Biotech Opportunities's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
RTW Biotech Opportunities (LSE:RTW) has a PS Ratio of 4.45 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RTW Biotech Opportunities and its competitors. This is near median its historical median of 4.10. Over the past decade, RTW Biotech Opportunities' PS Ratio has ranged from 2.33 to 17.68. According to the industry distribution chart, RTW Biotech Opportunities ranks #445 out of 1408 companies in the Asset Management industry, placing it in the top 31.6%.
Is RTW Biotech Opportunities' PS Ratio too high?
RTW Biotech Opportunities' current PS Ratio of 4.45 is near median its 10-year median of 4.10. Over the past 10 years, this metric has ranged from a low of 2.33 to a high of 17.68. The Asset Management industry median PS Ratio is 7.28. RTW Biotech Opportunities' value of 4.45 is 38.8% below this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #445 out of 1408 companies in the Asset Management industry, which is above the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' PS Ratio compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #445 out of 1408 companies for PS Ratio. This puts RTW Biotech Opportunities in the upper half of its industry. The industry median PS Ratio is 7.28. RTW Biotech Opportunities' value of 4.45 is 38.8% below this benchmark. Historically, RTW Biotech Opportunities' own PS Ratio has ranged from 2.33 to 17.68 over the past decade. While the company's 10-year median is 4.10 vs. the industry median of 7.28, RTW Biotech Opportunities has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for an Asset Management company?
The median PS Ratio among Asset Management companies is 7.28, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current PS Ratio of 4.45 is 38.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median PS Ratio is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current PS Ratio is 4.45, which is near median its own 10-year median of 4.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current PS Ratio of 4.45. The current PS Ratio is 4.45, which is near median its 10-year median of 4.10 and 38.8% below the Asset Management industry median of 7.28. RTW Biotech Opportunities' overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current PS Ratio is 4.45 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
42GF Score
Get the complete analysis for LSE:RTW
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
